lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   17 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Un estudio para evaluar Lanraplenib (LANRA) en combinación con Gilteritinib en participantes con leucemia mieloide aguda (LMA) en recidiva o resistente al tratamiento con mutaciones del gen FLT3

Not yet recruiting
1/2
55
Europe
Lanraplenib, Xospata, LANRA, Film-coated tablet, Xospata
Kronos Bio, Inc., Kronos Bio, Inc.
Acute Myeloid Leukemia Leucemia Mieloide Aguda, Acute Myeloid Leukemia Leucemia Mieloide Aguda, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio, Kronos Bio, Inc.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
ACTRN12616001548426: Evaluate the Pharmacokinetics of GS-9876 in Subjects with Impaired Renal Function

Recruiting
1
60
 
Gilead Sciences, Inc, Gilead Sciences, Inc
Inflammatory Diseases
 
 

Download Options